Based in San Diego, California, Proacta focuses on addressing unmet needs in cancer treatment by developing hypoxia-activated prodrugs that target cancer cells. These prodrugs selectively release active tyrosine-kinase inhibitors within the low-oxygen environment found in solid tumors, making them more effective and less toxic than current therapies. With a patent portfolio covering a series of hypoxia-activated prodrugs, Proacta's lead compound, PR610, shows promise in improving the outcomes of current treatment regimens. The company has raised $43 million in private financings from investors including Alta Partners, Clarus Ventures, and Roche. Proacta's goal is to develop a new generation of cancer drugs that target the specific physiological attributes of solid tumors.